These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2721108)

  • 1. Influence of coadministration on the pharmacokinetics of mezlocillin and cefotaxime in healthy volunteers and in patients with renal failure.
    Rodondi LC; Flaherty JF; Schoenfeld P; Barriere SL; Gambertoglio JG
    Clin Pharmacol Ther; 1989 May; 45(5):527-34. PubMed ID: 2721108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.
    Matzke GR; Abraham PA; Halstenson CE; Keane WF
    Clin Pharmacol Ther; 1985 Jul; 38(1):31-6. PubMed ID: 4006373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin.
    Flaherty JF; Barriere SL; Mordenti J; Gambertoglio JG
    Antimicrob Agents Chemother; 1987 Jun; 31(6):895-8. PubMed ID: 3619421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of cefotaxime in patients with chronic renal impairment (author's transl)].
    Fillastre JP; Ings RM; Leroy A; Humbert G; Godin M
    Nouv Presse Med; 1981 Feb; 10(8):574-9. PubMed ID: 6259595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of cefotaxime after a single intravenous dose in patients with impaired renal function.
    Moukhtar I; Nawishy S; Sabbour M
    Chemioterapia; 1987 Feb; 6(1):38-40. PubMed ID: 3829135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developmental pharmacokinetics of mezlocillin in 4 newborn infants.
    Jungbluth GL; Wirth FH; Rubio TT; Janicke DM; Jusko WJ
    Dev Pharmacol Ther; 1988; 11(6):317-21. PubMed ID: 3229277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of mezlocillin on the pharmacokinetics of oxacillin and dicloxacillin.
    Kampf D
    J Antimicrob Chemother; 1983 May; 11 Suppl C():25-32. PubMed ID: 6619039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent pharmacokinetics of mezlocillin in rats.
    Jungbluth GL; Jusko WJ
    Antimicrob Agents Chemother; 1989 Jun; 33(6):839-43. PubMed ID: 2764534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin.
    Kampf D; Schurig R; Weihermüller K; Förster D
    Antimicrob Agents Chemother; 1980 Jul; 18(1):81-7. PubMed ID: 6448024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doses of antibiotic in patients with renal insufficiency.
    Ohkawa M; Kuroda K
    Clin Ther; 1981; 4 Suppl A():124-32. PubMed ID: 6275994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cefodizime in normal individuals and in patients with renal failure.
    el Guinaidy MA; Nawishy S; Abd el Bary M; Sabbour MS
    Chemotherapy; 1991; 37(2):77-85. PubMed ID: 2032473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis.
    Ohkawa M; Okasho A; Motoi I; Tokunaga S; Shoda R; Kawaguchi S; Sawaki M; Shimamura M; Hirano S; Kuroda K; Awazu S
    Chemotherapy; 1983; 29(1):4-12. PubMed ID: 6299656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure.
    Rohde B; Werner U; Hickstein H; Ehmcke H; Drewelow B
    Eur J Clin Pharmacol; 1997; 53(2):111-5. PubMed ID: 9403281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function.
    Ings RM; Fillastre JP; Godin M; Leroy A; Humbert G
    Rev Infect Dis; 1982; 4 Suppl():S379-91. PubMed ID: 6294787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influence of fever on cefotaxime pharmacokinetics].
    Demotes-Mainard F; Albin H; Ragnaud JM; Gin H; Vincon G; Aubertin J
    Pathol Biol (Paris); 1988 Feb; 36(2):155-8. PubMed ID: 3279384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of mezlocillin disposition with a porcine model.
    DiPiro JT; Davis JB; Boudinot FD; Cheung RP; Sisley JF
    Biopharm Drug Dispos; 1989; 10(6):563-72. PubMed ID: 2611357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of mizolastine.
    Lebrun-Vignes B; Diquet B; Chosidow O
    Clin Pharmacokinet; 2001; 40(7):501-7. PubMed ID: 11510627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of infusion rate on pharmacokinetic parameters of azlocillin and mezlocillin].
    Haen E; Remien J; Richter E; Frank U; Adam D
    Arzneimittelforschung; 1985; 35(5):864-8. PubMed ID: 4026911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biliary excretion of mezlocillin in patients with hepatic disease.
    Hildebrandt R; Gundert-Remy U; Raedsch R; Sieg A; Stiehl A
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):384-7. PubMed ID: 7582392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the synergism of sulbactam and beta-lactam antibiotics under in vitro conditions and in healthy volunteers after intravenous administration. Antibacterial activity in vitro, compatibility and pharmacokinetics of the drugs in combination.
    Wildfeuer A; Schmalreck A; Räder K; Eibel G; Pfaff G
    Arzneimittelforschung; 1989 Jan; 39(1):94-100. PubMed ID: 2785802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.